ECOR vs STIM vs LIVN vs NVCR

For growth investors, Neuronetics, Inc.

(STIM) is the stronger pick with 99. 2% revenue growth year-over-year, versus 8. 3% for NovoCure Limited (NVCR). Analysts rate Neuronetics, Inc. (STIM) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, LivaNova PLC (LIVN) delivered a total return of -14.

5%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: LIVN returned +46. 2% versus ECOR's -97. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), LivaNova PLC (LIVN) is the lower-risk stock at 1.

29β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 70% more volatile than LIVN relative to the S&P 500. On balance sheet safety, LivaNova PLC (LIVN) carries a lower debt/equity ratio of 39% versus 3% for Neuronetics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Neuronetics, Inc.

(STIM) is pulling ahead at 99. 2% versus 8. 3% for NovoCure Limited (NVCR). On earnings-per-share growth, the picture is similar: Neuronetics, Inc. grew EPS 57. 2% year-over-year, compared to -483. 6% for LivaNova PLC. Over a 3-year CAGR, ECOR leads at 55. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

LivaNova PLC (LIVN) is the more profitable company, earning -17.

5% net margin versus -43. 6% for electroCore, Inc. — meaning it keeps -17. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LIVN leads at 14. 4% versus -41. 1% for ECOR. At the gross margin level — before operating expenses — ECOR leads at 86. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for STIM: 334.

8% to $8. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, LivaNova PLC (LIVN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.

29)). electroCore, Inc. (ECOR) carries a higher beta of 2. 06 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LIVN: +46. 2%, ECOR: -97. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ECOR is a small-cap high-growth stock; STIM is a small-cap high-growth stock; LIVN is a small-cap quality compounder stock; NVCR is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.